PDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES- LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN

Nov 1, 2005, 00:00 AM
10.1016/S1098-3015(10)67639-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)67639-5/fulltext
Section Title :
Section Order : 223
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67639-5&doi=10.1016/S1098-3015(10)67639-5
HEOR Topics :
Tags :
Regions :